NEW YORK, June 1, 2026, 10:06 (EDT)
- CODX dropped roughly 21% in early Nasdaq action, with shares last changing hands at $6.71.
- The SEC late Friday declared effective a Co-Diagnostics S-3 resale registration.
- The filing is for as many as 4.94 million shares from a private placement in May.
Co-Diagnostics shares dropped hard on the Nasdaq in early trading Monday. It was the first regular session after the U.S. Securities and Exchange Commission made effective a resale registration statement linked to a recent private placement.
The share price was at $6.71, down $1.83 from the $8.53 close on Friday. The stock swung between $5.11 and $10.18 during the session. The move pointed to high volatility in the small-cap diagnostics stock.
SEC notice accepted Monday, effective from 5:00 p.m. on May 29, lets selling stockholders use the S-3 registration, as long as they follow the prospectus terms.
S-3 filing includes up to 4,942,341 shares, a mix of common stock and shares that could come from pre-funded and common warrants tied to the May 21 private placement. Co-Diagnostics said in the filing it won’t get any money from resale of these shares, but it might see as much as $5.18 million if holders exercise the warrants for cash.
That’s what investors are focused on. A resale registration doesn’t mean the shares will hit the market right away, but it does open the door to more supply. The company also cautioned in the filing that sales, or even expectations of sales, could push the stock lower.
Co-Diagnostics said May 19 it signed a securities purchase deal with institutional investors for 1.65 million shares or pre-funded warrants, plus warrants for as many as 3.29 million more shares. The price per share or pre-funded warrant with attached warrants was $1.821. Maxim Group acted as sole placement agent.
Business prospects are back in view after the latest filings from Co-Diagnostics. The firm develops molecular diagnostic tests like PCR tests, a lab technique for amplifying genetic material to find infections. Co-Dx says its PCR platform is still under FDA review and can’t be sold yet, according to its filing.
Co-Diagnostics continued to spend ahead of running at full commercial scale. In its first-quarter numbers out May 14, the company posted $0.15 million in revenue, operating expenses of $9.2 million, and a net loss totaling $9.1 million. Cash and equivalents were $8.2 million as of March 31, down from $11.9 million at 2025 year-end.
Chief Executive Dwight Egan said in the release the company “generated the data needed” for a regulatory submission on its upper respiratory multiplex test and was preparing for an FDA 510(k) filing, the main premarket path for many medical devices. Egan also mentioned moves to begin clinical performance studies in India for the company’s tuberculosis program. PR Newswire
Sector tape traded weaker again, but losses were milder. The SPDR S&P Biotech ETF slipped around 1.8%. QuidelOrtho, which is in diagnostics, was off less than 1% early on.
Risks include pressure from selling stockholders, ongoing cash burn and slow regulatory timelines, which could outweigh near-term optimism for the pipeline. If warrant holders move to sell registered shares or exercise and don’t bring in much new cash, current shareholders might see more dilution. Delays with FDA or international commercialization could also mean the stock loses more of its recent rally.
